Diakonos Oncology headquarters details
- Street address
- 1110 NASA PARKWAYY SUITE 108I
- City
- Houston
- State / region
- Texas
- ZIP / postal code
- 77058
- Country
- United States
- Founded
- 2016
- Website
- diakonosoncology.com
Location map
Open in Google MapsAll Diakonos Oncology office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Houston HQ | Texas | United States | Headquarters |
About Diakonos Oncology
Diakonos Oncology is headquartered in Houston, Texas, United States. Founded in 2016, the company employs approximately 15 people worldwide.
Where is Diakonos Oncology's main office?
Diakonos Oncology's main headquarters office is located at 1110 NASA PARKWAYY SUITE 108I, Houston, Texas 77058, United States. This is the company's primary corporate address.
What does Diakonos Oncology do?
Diakonos Oncology focuses on developing dendritic cell vaccines to treat challenging cancer types, particularly glioblastoma. The company is in the clinical stage of its research, aiming to enhance cancer treatment through innovative immunotherapy approaches. Diakonos Oncology's lead product, DOC1021, is currently undergoing Phase II trials after receiving FDA Fast Track designation. The company actively presents its clinical findings at major medical conferences, showcasing the potential of its therapies to improve patient outcomes. Through its research efforts, Diakonos Oncology contributes to the advancement of cancer treatment options in the biotech field.
Frequently asked questions
Where is Diakonos Oncology headquarters?
Diakonos Oncology's headquarters is located at 1110 NASA PARKWAYY SUITE 108I, Houston, Texas 77058, United States.
What is Diakonos Oncology's corporate address?
The corporate headquarters address is 1110 NASA PARKWAYY SUITE 108I, Houston, Texas 77058, United States.
When was Diakonos Oncology founded?
Diakonos Oncology was founded in 2016 and employs approximately 15 people.
How many employees does Diakonos Oncology have?
Diakonos Oncology has approximately 15 employees (GraphIQ estimate, 2026).